Primary omecamtiv win is not enough
A theoretical pivotal trial success fails to back omecamtiv’s commercial promise and leaves Amgen’s pipeline in dire straits.
Bristol bets big on Myokardia
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
Fourth-quarter events to watch for big pharma
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
Biogen leads the way in renewed amyotrophic lateral sclerosis push
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
